In this video, Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses current and future treatment approaches to secondary fibrosis. Dr Mesa first highlights various agents used in the treatment of secondary myelofibrosis (MF), including pelabresib, navitoclax, and anti-fibrosing agents. Dr Mesa then discusses the role of interleukins in the process of developing MF, and how to improve treatment options for patients in the future. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
